Cargando…

Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments

OBJECTIVE: To evaluate physician risk-benefit preferences and trade-offs when making chemotherapy decisions for patients with non-small cell lung cancer (NSCLC). DESIGN: A discrete choice experiment (DCE). SETTINGS: Tertiary hospitals in Beijing, Shanghai, Guangzhou and Chengdu of China. PARTICIPANT...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hui, Wang, Huishan, Shi, Lizheng, Wang, Meifeng, Li, Junling, Shi, Jufang, Ni, Ming, Hu, Xianzhi, Chen, Yingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045216/
https://www.ncbi.nlm.nih.gov/pubmed/32051302
http://dx.doi.org/10.1136/bmjopen-2019-032336
_version_ 1783501735198720000
author Sun, Hui
Wang, Huishan
Shi, Lizheng
Wang, Meifeng
Li, Junling
Shi, Jufang
Ni, Ming
Hu, Xianzhi
Chen, Yingyao
author_facet Sun, Hui
Wang, Huishan
Shi, Lizheng
Wang, Meifeng
Li, Junling
Shi, Jufang
Ni, Ming
Hu, Xianzhi
Chen, Yingyao
author_sort Sun, Hui
collection PubMed
description OBJECTIVE: To evaluate physician risk-benefit preferences and trade-offs when making chemotherapy decisions for patients with non-small cell lung cancer (NSCLC). DESIGN: A discrete choice experiment (DCE). SETTINGS: Tertiary hospitals in Beijing, Shanghai, Guangzhou and Chengdu of China. PARTICIPANTS: The participants were 184 physicians (mean age of 37 years) with more than 1 year of NSCLC chemotherapy practice. OUTCOMES: The DCE survey was constructed by six attributes: progression-free survival (PFS), disease control rate (DCR), risk of moderate side effects, risk of severe side effects, mode of administration and out-of-pocket costs. Physicians’ relative preferences and trade-offs in patient out-of-pocket costs for each attribute level were estimated using a mixed logit model, and interaction terms were added to the model to assess preferences variation among physicians with different sociodemographic factors. RESULTS: Physicians had the strongest preferences for improvements in PFS, followed by reducing the risk of severe side effects. The DCR, risk of moderate side effects and mode of administration were ranked in decreasing order of importance. There was little variation in preferences among physicians with different sociodemographic characteristics. Physicians were willing to trade $4814 (95% CI $4149 to $5480) of patient out-of-pocket costs per month for a chemotherapy that guaranteed 11 months of PFS, followed by $1908 (95% CI $1227 to $2539) for reducing the risk of severe side effects to 2%. CONCLUSIONS: With regard to chemotherapy for patients with NSCLC, prolonging PFS, reducing severe and moderate side effects were primary considerations for physicians in China. The mode of administration and treatment costs significantly influenced physicians’ therapeutic decision. The current findings could add some evidence to inform NSCLC chemotherapy implementation and promote shared decision-making.
format Online
Article
Text
id pubmed-7045216
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70452162020-03-09 Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments Sun, Hui Wang, Huishan Shi, Lizheng Wang, Meifeng Li, Junling Shi, Jufang Ni, Ming Hu, Xianzhi Chen, Yingyao BMJ Open Health Services Research OBJECTIVE: To evaluate physician risk-benefit preferences and trade-offs when making chemotherapy decisions for patients with non-small cell lung cancer (NSCLC). DESIGN: A discrete choice experiment (DCE). SETTINGS: Tertiary hospitals in Beijing, Shanghai, Guangzhou and Chengdu of China. PARTICIPANTS: The participants were 184 physicians (mean age of 37 years) with more than 1 year of NSCLC chemotherapy practice. OUTCOMES: The DCE survey was constructed by six attributes: progression-free survival (PFS), disease control rate (DCR), risk of moderate side effects, risk of severe side effects, mode of administration and out-of-pocket costs. Physicians’ relative preferences and trade-offs in patient out-of-pocket costs for each attribute level were estimated using a mixed logit model, and interaction terms were added to the model to assess preferences variation among physicians with different sociodemographic factors. RESULTS: Physicians had the strongest preferences for improvements in PFS, followed by reducing the risk of severe side effects. The DCR, risk of moderate side effects and mode of administration were ranked in decreasing order of importance. There was little variation in preferences among physicians with different sociodemographic characteristics. Physicians were willing to trade $4814 (95% CI $4149 to $5480) of patient out-of-pocket costs per month for a chemotherapy that guaranteed 11 months of PFS, followed by $1908 (95% CI $1227 to $2539) for reducing the risk of severe side effects to 2%. CONCLUSIONS: With regard to chemotherapy for patients with NSCLC, prolonging PFS, reducing severe and moderate side effects were primary considerations for physicians in China. The mode of administration and treatment costs significantly influenced physicians’ therapeutic decision. The current findings could add some evidence to inform NSCLC chemotherapy implementation and promote shared decision-making. BMJ Publishing Group 2020-02-12 /pmc/articles/PMC7045216/ /pubmed/32051302 http://dx.doi.org/10.1136/bmjopen-2019-032336 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health Services Research
Sun, Hui
Wang, Huishan
Shi, Lizheng
Wang, Meifeng
Li, Junling
Shi, Jufang
Ni, Ming
Hu, Xianzhi
Chen, Yingyao
Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
title Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
title_full Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
title_fullStr Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
title_full_unstemmed Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
title_short Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments
title_sort physician preferences for chemotherapy in the treatment of non-small cell lung cancer in china: evidence from multicentre discrete choice experiments
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045216/
https://www.ncbi.nlm.nih.gov/pubmed/32051302
http://dx.doi.org/10.1136/bmjopen-2019-032336
work_keys_str_mv AT sunhui physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT wanghuishan physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT shilizheng physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT wangmeifeng physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT lijunling physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT shijufang physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT niming physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT huxianzhi physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments
AT chenyingyao physicianpreferencesforchemotherapyinthetreatmentofnonsmallcelllungcancerinchinaevidencefrommulticentrediscretechoiceexperiments